Hamilton Thorne appoints Feng Han to its Board as Independent Director

– USA, MA –  Hamilton Thorne Ltd. (TSX: HTL), a leading provider of precision instruments, consumables, software, and services to the Assisted Reproductive Technologies, research, and cell biology markets, today announced the appointment of Feng Han to its Board as an independent director, effective February 15, 2021.

“We are delighted to have Feng join our Board of Directors,” said CEO, David Wolf. “As much of the long-term growth in our field will be in Asia, and the Hamilton Thorne growth strategy includes an ongoing merger and acquisitions program, Feng’s extensive experience in global operations and M&A, with particular expertise in Asia, will be invaluable.”

The company also announced that Dean Gendron, a co-founder of Calotto Capital, Hamilton Thorne’s predecessor company, will retire from the Board of Directors.

David Wolf added, “I would like to personally thank and recognize Dean for his significant and continued contributions to Hamilton Thorne. As the founder and former CEO of Calotto Capital, Dean played a key role in Hamilton Thorne’s listing on the TSX Venture Exchange and its initial financing rounds. I look forward to continuing to work with Dean as we drive the growth of our Company.”

About Feng Han

Mr. Han is currently a partner at Pagoda Capital, a private equity firm that focuses on healthcare and technology, based in Beijing, Hong Kong, and New York. Mr. Han has over 25 years of healthcare operational and investment experience in the U.S., Europe, and Asia across healthcare sectors including emerging technology, med-tech, and services. Previously, Mr. Han was Managing Director at Fosun International (00656.HK) where he managed U.S. healthcare investment activities, and Director of Corporate Business Development at Henry Schein (NASDAQ: HSIC) where he led mergers and acquisitions in Asia.

Mr. Han holds an MBA from The Wharton School, University of Pennsylvania, an MS from Michigan State University in Microbiology and Molecular Genetics, and a BS from Shandong University in Microbial Engineering.

About Hamilton Thorne Ltd.

Hamilton Thorne is a leading global provider of precision instruments, consumables, software, and services that reduce cost, increase productivity, improve results and enable breakthroughs in Assisted Reproductive Technologies, research, and cell biology markets. Hamilton Thorne markets its products and services under the Hamilton Thorne, Gynemed, Planer, and Embryotech Laboratories brands, through its growing sales force and distributors worldwide. Hamilton Thorne’s customer base consists of fertility clinics, university research centers, animal breeding facilities, pharmaceutical companies, biotechnology companies, and other commercial and academic research establishments.

For more information: https://www.hamiltonthorne.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team